Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

被引：10
|
作者：
Ettl, Johannes [1 ]
机构：
[1] Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
来源：
BREAST CARE | 2016年 / 11卷 / 03期
关键词：
Advanced breast cancer; Palbociclib; CDK4/6; Endocrine therapy; Cell cycle; DEPENDENT KINASE 4/6; 1ST-LINE TREATMENT; SUBGROUP ANALYSIS; LETROZOLE L; PD; 0332991; PALOMA-1/TRIO-18; COMBINATION; TRIAL; EFFICACY; SAFETY;
D O I：
10.1159/000447417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed. (C) 2016 S. Karger GmbH, Freiburg
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [41] A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
    Yang, Liu
    Chen, Yang
    Wang, Ning
    Han, Weiwei
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [42] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Esther S. Kim
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 373 - 383
  • [43] Adjuvant CDK4/6 inhibitors: can they improve clinical outcomes in hormone receptor-positive (HR+) early breast cancer?
    Johnston, Stephen R. D.
    ANNALS OF PALLIATIVE MEDICINE, 2023,
  • [44] An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
    Robert, Marie
    Frenel, Jean-Sebastien
    Bourbouloux, Emmanuelle
    Rigaud, Dominique Berton
    Patsouris, Anne
    Augereau, Paule
    Gourmelon, Carole
    Campone, Mario
    DRUGS, 2018, 78 (13) : 1353 - 1362
  • [45] Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
    Guillaume, Zoe
    Medioni, Jacques
    Lillo-Lelouet, Agnes
    Marret, Gregoire
    Oudard, Stephane
    Simonaggio, Audrey
    CLINICAL BREAST CANCER, 2020, 20 (02) : E192 - E195
  • [46] Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR plus advanced breast cancer: a systematic review and meta-analysis
    Guan, Xin
    Li, Mengyuan
    Ji, Xinyue
    Wang, Yufei
    Tian, Lei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [47] CDK4/6 inhibitors in HER2-positive breast cancer
    Corona, Silvia Paola
    Ravelli, Andrea
    Cretella, Daniele
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Dester, Martina
    Gobbi, Angela
    Petronini, Pier Giorgio
    Generali, Daniele
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 112 : 208 - 214
  • [48] Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment
    Ballestin, Sonia Santander
    Labena, Maria Abadia
    Avedillo-Salas, Ana
    Continente, Cristina Marco
    Blazquez, Marina Arribas
    Bartolome, Maria Jose Luesma
    CANCERS, 2025, 17 (05)
  • [49] Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer
    Gnant, Michael
    Balic, Marija
    Singer, Christian F.
    Rinnerthaler, Gabriel
    Pfeiler, Georg
    Suppan, Christoph
    Gruenberger, Birgit
    Strasser-Weippl, Kathrin
    Castagnaviz, Vanessa
    Heibl, Sonja
    Bartsch, Rupert
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2025, 18 (01) : 4 - 18
  • [50] CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
    de Melo Gagliato, Debora
    Buzaid, Antonio C.
    Manuel Perez-Garcia, Jose
    Llombart, Antonio
    Cortes, Javier
    CANCERS, 2020, 12 (09) : 1 - 19
12345